Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H18N8O5 |
Molecular Weight | 390.354 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=CN(N=C1)C2=NC3=C(N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)C(N)=N2
InChI
InChIKey=LZPZPHGJDAGEJZ-AKAIJSEGSA-N
InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1
Molecular Formula | C15H18N8O5 |
Molecular Weight | 390.354 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001176/WC500097103.pdf | https://ec.europa.eu/health/documents/community-register/2014/20140116127516/anx_127516_en.pdf | https://www.drugs.com/ppa/regadenoson.html
Curator's Comment: description was created based on several sources, including:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001176/WC500097103.pdf | https://ec.europa.eu/health/documents/community-register/2014/20140116127516/anx_127516_en.pdf | https://www.drugs.com/ppa/regadenoson.html
Regadenoson (Lexiscan), a low affinity agonist of the A2A adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries. It is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The most common adverse reactions to Lexiscan are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. Methylxanthines, e.g., caffeine and theophylline, may interfere with the activity of Lexiscan. Aminophylline may be used to attenuate severe and/or persistent adverse reactions to Lexiscan.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL226 |
16.0 µM [Ki] | ||
Target ID: CHEMBL251 |
1.3 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | LEXISCAN Approved UseLexiscan® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress (1). Launch Date1.20778562E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.6 ng/mL |
400 μg single, intravenous dose: 400 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
REGADENOSON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.7 ng × h/mL |
400 μg single, intravenous dose: 400 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
REGADENOSON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h |
400 μg single, intravenous dose: 400 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
REGADENOSON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Sources: Page: 1211Palpitation (3 patients) Flushing (3 patients) Shortness of breath (4 patients) Nausea and vomiting (5 patients) Change in ECG (1 patient) Headache (4 patients) |
10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Sources: Page: 1211Palpitation (3 patients) Dizziness (3 patients) Shortness of breath (1 patient) Nausea and vomiting (2 patients) Headache (3 patients) |
10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Palpitation, Dizziness... Other AEs: Palpitation (4 patients) Sources: Page: 1211Dizziness (2 patients) Flushing (4 patients) Shortness of breath (2 patients) Change in ECG (1 patient) Headache (1 patient) |
20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (2 patients) Sources: Page: 1211Palpitation (2 patients) Dizziness (3 patients) Flushing (1 patient) Nausea and vomiting (4 patients) Headache (3 patients) |
20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Sources: Page: 1211Palpitation (4 patients) Dizziness (3 patients) Flushing (8 patients) Shortness of breath (3 patients) Nausea and vomiting (3 patients) Change in ECG (7 patients) Headache (7 patients) |
3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Palpitation, Dizziness... Other AEs: Palpitation (2 patients) Sources: Page: 1211Dizziness (1 patient) Flushing (1 patient) Change in ECG (3 patients) |
3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Sources: Page: 1211Palpitation (2 patients) Dizziness (1 patient) Flushing (3 patients) Shortness of breath (1 patient) Change in ECG (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Change in ECG | 1 patient | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 1 patient | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 3 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 3 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 4 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 4 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Nausea and vomiting | 5 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 1 patient | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 1 patient | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Nausea and vomiting | 2 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 3 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 3 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 3 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Change in ECG | 1 patient | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 1 patient | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 2 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 2 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 4 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 4 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 1 patient | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 2 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 2 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Nausea and vomiting | 4 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 1 patient | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Nausea and vomiting | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 4 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Change in ECG | 7 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 7 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 8 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 2 patients | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Change in ECG | 3 patients | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Change in ECG | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 2 patients | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 3 patients | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.astellas.us/docs/lexiscan.pdf
5 mL (0.4 mg) by rapid injection; followed immediately by saline flush and
radiopharmaceutical.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26626489
10 nM CVT-3146 decreased coronary perfusion pressure by 23 mm Hg in rat isolated perfused heart.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:34:22 UTC 2023
by
admin
on
Fri Dec 15 15:34:22 UTC 2023
|
Record UNII |
7AXV542LZ4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000178375
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
||
|
WHO-ATC |
C01EB21
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1546015
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | RxNorm | ||
|
7AXV542LZ4
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | |||
|
219024
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | |||
|
7AXV542LZ4
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | |||
|
C171933
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | |||
|
m9517
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB30494
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | |||
|
DTXSID4057712
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | |||
|
313348-27-5
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | |||
|
8488
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY | |||
|
DB06213
Created by
admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||